Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 6, 2010, Pages 1243-1251

  Oo, Thein Zaw ^a,b,c   Cole, Nerida ^a,b,c   Garthwaite, Linda ^a   Willcox, Mark D P ^a,b,c   Zhu, Hua ^a,b,c  

^a BRIEN HOLDEN VISION INSTITUTE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c VISION COOPERATIVE RESEARCH CENTRE   (Australia)

Author keywords

Ciprofloxacin; keratitis; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; LACTOFERRICIN B; MYELOPEROXIDASE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; KERATITIS; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CORNEAL DISEASES; DRUG SYNERGISM; LACTOFERRIN; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 77953533205     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq106     Document Type: Article

References (58)

1. Baum J, Barza M. The evolution of antibiotic therapy for bacterial conjunctivitis and keratitis: 1970-2000. Cornea 2000; 19: 659-72.
2. Oudhuis GJ, Verbon A, Hoogkamp-Korstanje JA et al. Antimicrobial resistance in Escherichia coli and Pseudomonas aeruginosa from intensive care units in the Netherlands, 1998-2005. Int J Antimicrob Agents 2008; 31: 58-63.
3. Wimmerstedt A, Kahlmeter G. Associated antimicrobial resistance in Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes. Clin Microbiol Infect 2008; 14: 315-21.
4. Kunimoto DY, Sharma S, Garg P et al. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology 1999; 106:80-5.
5. Asbell P, Stenson S. Ulcerative keratitis. Survey of 30 years' laboratory experience. Arch Ophthalmol 1982; 100: 77-80.
6. Willcox M, Sankaridurg P, Zhu H. Inflammation and infection and effects of the closed eye. In: Sweeney D, ed. Silicones Hydrogels: Continuous Wear Contact Lens. 2nd edn. London: Butterworth-Heinemann, 2004; 90-125.
7. Zhu H, Conibear T, Bandara R et al. Type III secretion system-associated toxins, proteases, serotypes and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis. Curr Eye Res 2006; 31: 297-306.
8. Schubert TL, Hume EB, Willcox MD. Staphylococcus aureus ocular isolates from symptomatic adverse events: antibiotic resistance and similarity of bacteria causing adverse events. Clin Exp Optom 2008; 91: 148-55.
9. Marangon FB, Miller D, Muallem MS et al. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 2004; 137:453-8.
10. Choy MH, Stapleton F, Willcox MDP et al. Comparison of virulence factors in Pseudomonas aeruginosa strains isolated from contact lensand non-contact lens-related keratitis. J Med Microbiol 2008; 57: 1539-46.
11. Gangopadhyay N, Daniell M, Weih L et al. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol 2000; 84: 378-84.
12. Rudd JC, Moshirfar M. Methicillin-resistant Staphylococcus aureus keratitis after laser in situ keratomileusis. J Cataract Refract Surg 2001; 27: 471-3.
13. Van der Auwera P, Legrand JC. Ticarcillin-clavulanic acid therapy in severe infections. Drugs Exp Clin Res 1985; 11: 805-13.
14. Ellis-Pegler RB, Lang SD, Downey DJ et al. Augmentin treatment of bacterial infections in hospitalised patients. N Z Med J 1982; 95: 542-5.
15. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999; 27: S24-8.
16. Hilf M, Yu VL, Sharp J et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-6.
17. Scott MG, Hancock RE. Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol 2000; 20: 407-31.
18. Giacometti A, Cirioni O, Barchiesi F et al. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother 1999; 44: 641-5.
19. Brogden K. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Microbiology 2005; 3: 238-50.
20. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1: 156-64.
21. Tomita M, Wakabayashi H, Shin K et al. Twenty-five years of research on bovine lactoferrin applications. Biochimie 2009; 91:52-7.
22. Bellamy W, Takase M, Yamauchi K et al. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992; 1121: 130.
23. Yamauchi K, Tomita M, Giehl TJ et al. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993; 61: 719-28.
24. Vorland L, Ulvatne H, Andersen J et al. Lactoferricin of bovine origin is more active than lactoferricin of human, murine and caprine origin. Scand J Infect Dis 1998; 30: 513-7.
25. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
26. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
27. Cole N, Krockenberger M, Stapleton F et al. Experimental Pseudomonas aeruginosa keratitis in interleukin-10 gene knockout mice. Infect Immun 2003; 71: 1328-36.
28. Isenberg HD. Clinical Microbiology Procedure Hand Book. Washington, DC: American Society for Microbiology Press, 2004.
29. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52:1.
30. Pillai SK, Moellering RC Jr, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 5th edn. Philadelphia: Lippincott Williams and Wilkins, 2005; 365-440.
31. Ednie LM, Credito KL, Khantipong M et al. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods. J Antimicrob Chemother 2000; 45: 633-8.
32. Dionysius DA, Milne JM. Antibacterial peptides of bovine lactoferrin: purification and characterization. J Dairy Sci 1997; 80: 667-74.
33. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005; 62: 2588-98.
34. Kang JH, Lee MK, Kim KL et al. Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int J Pept Protein Res 1996; 48: 357-63.
35. Vorland LH, Osbakk SA, Perstolen T et al. Interference of the antimicrobial peptide lactoferricin B with the action of various antibiotics against Escherichia coli and Staphylococcus aureus. Scand J Infect Dis 1999; 31: 173-7.
36. Bellamy W, Takase M, Wakabayashi H et al. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 1992; 73: 472-9.
37. Wakabayashi H, Teraguchi S, Tamura Y. Increased Staphylococcuskilling activity of an antimicrobial peptide, lactoferricin B, with minocycline and monoacylglycerol. Biosci Biotech Biochem 2002; 66: 2161-7.
38. Naidu SS, Svensson U, Kishore AR et al. Relationship between antibacterial activity and porin binding of lactoferrin in Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother 1993; 37: 240-5.
39. Stermitz FR, Lorenz P, Tawara JN et al. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000; 97: 1433-7.
40. Minahk CJ, Dupuy F, Morero RD. Enhancement of antibiotic activity by sub-lethal concentrations of enterocin CRL35. J Antimicrob Chemother 2004; 53: 240-6.
41. Campos MA, Morey P, Bengoechea JA et al. Quinolones sensitize Gram-negative bacteria to antimicrobial peptides. Antimicrob Agents Chemother 2006; 50: 2361-7.
42. Ulvatne H, Samuelsen O, Haukland HH et al. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 2004; 237: 377-84.
43. Jutila A, Rytömaa M, Kinnunen PKJ. Detachment of cytochrome c by cationic drugs from membranes containing acidic phospholipids: comparison of lidocaine, propranolol, and gentamycin. Mol Pharmacol 1998; 54: 722-32.
44. Vorland LH, Ulvatne H, Rekdal O et al. Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand J Infect Dis 1999; 31: 467-73.
45. Diarra MS, Petitclerc D, Lacasse P. Effect of lactoferrin in combination with penicillin on the morphology and the physiology of Staphylococcus aureus isolated from bovine mastitis. J Dairy Sci 2002; 85: 1141-9.
46. Diarra MS, Lacasse P, Deschenes E et al. Ultrastructural and cytochemical study of cell wall modification by lactoferrin, lactoferricin and penicillin G against Staphylococcus aureus. J Electron Microsc (Tokyo) 2003; 52: 207-15.
47. Krogstad D, Moellering R. Antimicrobial combination. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore: Williams & Wilkins, 1986; 537-48.
48. Gachon A-M, Richard J, Dastugue B. Human tears: normal protein pattern and individual protein determinations in adults. Curr Eye Res 1982; 2: 301-8.
49. Hume EBH, Cole N, Parmar A et al. Secretory phospholipase A2 deposition on contact lenses and its effect on bacterial adhesion. Invest Ophthalmol Vis Sci 2004; 45: 3161-4.
50. Facon MJ, Skura BJ. Antibacterial activity of lactoferricin, lysozyme and EDTA against Salmonella enteritidis. Int Dairy J 1996; 6: 303-13.
51. Forst S, Weiss J, Elsbach P. The role of phospholipase A2 lysines in phospholipolysis of Escherichia coli killed by a membrane-active neutrophil protein. J Biol Chem 1982; 257: 14055-7.
52. Vandermee T, Menconi M, Zhaung J et al. Protective effects of a novel 32-amino acid C-terminal fragment of CAP 18 in endoxemic pigs. Surgery 1995; 117: 656-62.
53. Hirata M, Shimomura Y, Yoshida M et al. Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect Immun 1994; 62: 1421-6.
54. Sawa T. Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model. Antimicrob Agents Chemother 1998; 42: 3269-75.
55. Ueta E, Tanida T, Osaki T. A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J Pept Res 2001; 57: 240-9.
56. Hazlett LD, McClellan S, Kwon B et al. Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive. Invest Ophthalmol Vis Sci 2000; 41: 805-10.
57. Guarna Marta M, Coulson R, Rubinchik E. Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris. FEMS Microbiol Lett 2006; 257:1-6.
58. Samuelsen O, Haukland HH, Ulvatne H et al. Anti-complement effects of lactoferrin-derived peptides. FEMS Immunol Med Microbiol 2004; 41: 141-8.